Business Wire

CyberArk Named a Leader in the 2024 Gartner® Magic Quadrant™ for Privileged Access Management

11.9.2024 18:04:00 EEST | Business Wire | Press release

Share

CyberArk (NASDAQ: CYBR), the identity security company, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Privileged Access Management.1 CyberArk is positioned as a Leader for the sixth consecutive time and is positioned furthest in Completeness of Vision, which evaluates vendors on offering (product) strategy, innovation and market understanding among other evaluation criteria.

With 93% of organizations suffering two or more identity-related breaches in the last 12 months, managing and securing identities has become a critical requirement. The CyberArk Identity Security Platform enables organizations to secure the entire spectrum of identities, including workforce, IT, developer and machine, supporting modern access use cases such as the need to enforce Zero Standing Privileges in public cloud environments. A core component of the platform is CyberArk’s privileged access management (PAM) capabilities, which allow customers to apply flexible privilege controls to help prevent malicious account, credential and secrets access throughout the entire enterprise infrastructure.

“We are incredibly proud to once again be named a Leader by Gartner. CyberArk delivers identity security programs for a multi-cloud world. We feel that our position as a Leader in this year’s report, for the sixth consecutive time, is a testament to our commitment to ongoing innovation and customer success,” said Matt Cohen, CEO, CyberArk. “Identity security is no longer just about human identities. As identities – especially machine identities - proliferate, driven by new hybrid and multi-cloud environments, an effective identity security strategy must secure them all with the right level of privilege controls. CyberArk’s advanced PAM, secrets management and endpoint privilege security capabilities are key to empowering our customers to secure every identity and defend against cyberattacks.”

CyberArk aims to deliver the industry’s most comprehensive identity security platform, including:

  • Outstanding Customer Experience: CyberArk is committed to a customer-first approach, ensuring that all identities are secured with the right level of privilege controls, while putting the customer at the center of all it does. Its unified, SaaS-based platform notably simplifies and improves the administrator and end user experience to reduce cost and complexity, helping organizations accelerate their migration to the cloud with consistent identity security controls in place.
  • PAM Programs for a Multi-Cloud World: The CyberArk Identity Security Platform provides best-in-class, end-to-end PAM capabilities. CyberArk centrally and natively secures both shared and federated privileged access for IT and cloud ops teams supporting digital initiatives. By applying intelligent privilege controls within native tooling, CyberArk helps PAM programs scale across all environments – from long-lived systems in on-premises data centers to elastic cloud workloads, public cloud services and SaaS apps.
  • Unified, Cross-Platform Innovation, Powered by AI: CyberArk recently introduced new capabilities for securing every identity, further extending PAM controls to all identity types, including workforce identities. Offerings now include support for secure standing access and zero standing privileges, with the ability to isolate and audit privileged sessions. In addition, CyberArk Endpoint Privilege Manager now offers strong end-to-end passwordless authentication when signing into endpoints and elevating application controls. CyberArk’s unified portal means that the end user experience is enhanced with one-click, native access to enterprise resources, while intelligent privilege controls protect the user. Earlier this year, CyberArk also announced CORA AI™, which will allow organizations to analyze anomalies and apply next-level identity threat detection and response actions, reducing reaction times from hours to minutes.
  • World-Leading Partner Support and Technology Ecosystem: CyberArk aims to make it easier for partners to develop deep identity security practices and measurably reduce cybersecurity risk for customers. CyberArk invests heavily in its Channel Partner Program, with the launch of a new self-service portal for partners – as well as the CyberArk MSP Console - and new certifications underscoring its commitment to value creation for both joint customers and partners. CyberArk’s global ecosystem brings together more than 1,300 system integrators, managed service providers, strategic outsourcers, advisories, solution providers, distributors and marketplaces. Alongside this partner network, the CyberArk C3 technology alliance allows customers to make the most of their existing technology investments, featuring more than 200 certified integrations from providers of enterprise software, infrastructure and security solutions.

To download a complimentary copy of the 2024 Gartner Magic Quadrant for Privileged Access Management visit: https://www.cyberark.com/gartner-2024-mq-pam

1 – Gartner® Magic Quadrant™ for Privileged Access Management, by Abhyuday Data, Michael Kelley, Nayara Sangiorgio, Felix Gaehtgens, Paul Mezzera, 9 September 2024

Gartner Disclaimers

GARTNER is a registered trademarks and service mark, and MAGIC QUADRANT is a registered trademark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and are used herein with permission. All rights reserved.

Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

About CyberArk

CyberArk (NASDAQ: CYBR) is the global leader in identity security. Centered on intelligent privilege controls, CyberArk provides the most comprehensive security offering for any identity – human or machine – across business applications, distributed workforces, hybrid cloud environments and throughout the DevOps lifecycle. The world’s leading organizations trust CyberArk to help secure their most critical assets. To learn more about CyberArk, visit https://www.cyberark.com, read the CyberArk blogs or follow on LinkedIn, X, Facebook or YouTube.

Copyright © 2024 CyberArk Software. All Rights Reserved. All other brand names, product names, or trademarks belong to their respective holders.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240910351926/en/

Contacts

Investor Relations:
Srinivas Anantha, CFA
CyberArk
617-558-2132
ir@cyberark.com

Media:
Nick Bowman
CyberArk
+44 (0) 7841 673378
press@cyberark.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 17:00:00 EEST | Press release

PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpinned by global capacity, technical expertise, deep scientific knowledge, and an industry-leading quality and regulatory track record. This press release features multimedia. View the full release here: https://www.

Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 16:53:00 EEST | Press release

Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor

Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 16:00:00 EEST | Press release

Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world. “Data is only valuable when it’s activated,” said Steve Lucas, Chairman and CEO, Boomi. “At Boomi World 2026, we

Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 16:00:00 EEST | Press release

Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level in our clients’ complex matters,” said Jeny Maier, managing partner

Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 16:00:00 EEST | Press release

Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug conjugates (ADCs). Central to Araris’ approach is its proprietary AraLinQ™ ADC technology, which enables the creation of stable and site-specific ADCs using standard antibodies with scalable manufacturing

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye